{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:07Z","timestamp":1790344927473,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lungcan.2026.109470","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:24:45Z","timestamp":1779675885000},"page":"109470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7911","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-9259","authenticated-orcid":false,"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Koto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-1056","authenticated-orcid":false,"given":"Takehiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-5850","authenticated-orcid":false,"given":"Mizue","family":"Ogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-1828","authenticated-orcid":false,"given":"Chikako","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-1213","authenticated-orcid":false,"given":"Hiroshi","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0853","authenticated-orcid":false,"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109470_b0005","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2026.109470_b0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109470_b0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0020","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1002\/cam4.3306","article-title":"Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study","volume":"9","author":"Horinouchi","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.109470_b0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109470_b0035","unstructured":"A. Balaji, F. Verde, K. Suresh, J. Naidoo, Pneumonitis from anti-PD-1\/ PD-L1 therapy, Oncology (Williston Park). 31 (2017) 739\u2013746, 754."},{"key":"10.1016\/j.lungcan.2026.109470_b0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2026.109470_b0045","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2026.109470_b0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","volume":"25","author":"Long","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2026.109470_b0055","unstructured":"Japan Pharmaceuticals and Medical Devices Agency (PMDA). Durvalumab prescribing information, https:\/\/www.pmda.go.jp\/files\/000238551.pdf. [accessed 21 June 2025]."},{"key":"10.1016\/j.lungcan.2026.109470_b0060","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2016.12.030","article-title":"Continuous activity monitoring during concurrent chemoradiotherapy","volume":"97","author":"Ohri","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109470_b0065","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109470_b0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41746-020-00363-7","article-title":"Assessment of physiological signs associated with COVID-19 measured using wearable devices","volume":"3","author":"Natarajan","year":"2020","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.lungcan.2026.109470_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109470_b0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109470_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109470_b0090","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1214\/aos\/1176344198","article-title":"Nonparametric estimation of partial transition probabilities in multiple decrement models","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann. Stat."},{"key":"10.1016\/j.lungcan.2026.109470_b0095","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00330-011-2098-2","article-title":"Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality","volume":"21","author":"Edey","year":"2011","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.lungcan.2026.109470_b0100","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01634-2022","article-title":"A predictive model for acute exacerbation of idiopathic interstitial pneumonias","volume":"61","author":"Karayama","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109470_b0105","article-title":"Pilot study of a wearable activity monitor during head and neck radiotherapy to predict clinical outcomes","volume":"6","author":"Sher","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.lungcan.2026.109470_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2019.05.005","article-title":"Fitbit usage in patients with breast cancer undergoing chemotherapy","volume":"19","author":"Dreher","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.lungcan.2026.109470_b0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/1534735416684016","article-title":"Assessing the correlation between physical activity and quality of life in advanced lung cancer","volume":"17","author":"Bade","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109470_b0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.sleh.2014.12.010","article-title":"National Sleep Foundation\u2019s sleep time duration recommendations: methodology and results summary","volume":"1","author":"Hirshkowitz","year":"2015","journal-title":"Sleep Health"},{"key":"10.1016\/j.lungcan.2026.109470_b0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jtho.2025.08.010","article-title":"Long-term safety and effectiveness of durvalumab in unresectable stage III NSCLC in Japan: a multicenter prospective study (AYAME)","volume":"21","author":"Kenmotsu","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0135","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0355-2020","article-title":"Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency","volume":"30","author":"Gille","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lungcan.2026.109470_b0140","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/s22062264","article-title":"Use of a wearable biosensor to study heart rate variability in chronic obstructive pulmonary disease and its relationship to disease severity","volume":"22","author":"Park","year":"2022","journal-title":"Sensors (basel)"},{"key":"10.1016\/j.lungcan.2026.109470_b0145","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/thoraxjnl-2020-216749","article-title":"Nocturnal hypoxaemia in interstitial lung disease: a systematic review","volume":"76","author":"Khor","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.lungcan.2026.109470_b0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0360-3016(99)00183-2","article-title":"Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)","volume":"45","author":"Graham","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109470_b0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0360-3016(02)03807-5","article-title":"Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer","volume":"55","author":"Tsujino","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3 Suppl","key":"10.1016\/j.lungcan.2026.109470_b0160","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109470_b0165","article-title":"Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab","volume":"8","author":"Diamond","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cllc.2024.02.006","article-title":"Durvalumab consolidation after chemoradiotherapy in elderly patients with unresectable stage III NSCLC: a real-world multicenter study","volume":"25","author":"Park","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109470_b0175","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jtho.2020.05.007","article-title":"Multidisciplinary approach of immune checkpoint inhibitor-related pneumonitis: a key to address knowledge and management gaps","volume":"15","author":"P\u00e9rol","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0180","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109470_b0185","first-page":"0360","article-title":"Crosstalk between exercise and immunotherapy: current understanding and future directions","volume":"7","author":"Liu","year":"2024","journal-title":"Research (Wash DC)."},{"key":"10.1016\/j.lungcan.2026.109470_b0190","doi-asserted-by":"crossref","first-page":"e1471","DOI":"10.1002\/cti2.1471","article-title":"Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions","volume":"12","author":"Hoeh","year":"2023","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.lungcan.2026.109470_b0195","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/cells12091281","article-title":"Circulatory serum Krebs von Den Lungen-6 and surfactant protein-D concentrations predict interstitial lung disease progression and mortality","volume":"12","author":"Rai","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.lungcan.2026.109470_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1181248","article-title":"Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Rugambwa","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:28:18Z","timestamp":1790342898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S0169500226005313"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109470","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109470"}}